ClinicalTrials.gg
RecruitingNCT05837286Updated Mar 27, 2026

Conservative Treatment of Trigger Finger

An interventional study of Oval-8 ® Orthosis and Cortisone injection only in Hand Injuries and Trigger Finger, sponsored by Cedars-Sinai Medical Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This study is to analyze the effectiveness of a nighttime extension orthosis after receiving a cortisone injection for the treatment of trigger finger to improve pain and restore functional outcomes. The investigators hypothesize that the extension orthosis will improve pain and functional outcomes compared to those without a digital night extension orthosis in those with trigger finger at 12 weeks from the injection.

Read the detailed description

The purpose of the research is to analyze the effectiveness of a proximal interphalangeal joint (PIPJ) extension night orthosis status-post cortisone injection of the first annular pulley for the treatment of trigger finger to improve pain and restore functional outcomes. The investigators hypothesize that the extension orthosis will improve pain and functional outcomes (Quick Dash score) compared to those without a digital night extension orthosis in those with trigger finger at 12 weeks from the injection.

02

Conditions studied

  • Hand Injuries
  • Trigger Finger
03

In context

Hand Injuries

122 studies on the registry are indexed under Hand Injuries; 35 are open to participants now.

This study's planned enrollment of 146 is above the median of 55 across 97 interventional studies indexed under Hand Injuries.

Browse Hand Injuries studies →

Lead sponsor

Cedars-Sinai Medical Center is the lead sponsor of 456 studies on the registry; 107 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals 18 years old or older are included
  • Patients with trigger finger, aka stenosing flexor tenosynovitis
  • Status post receiving cortisone injection of the affected digit(s)

Exclusion criteria

Exclusion Criteria:

  • Any records flagged with break the glass or research opt out
  • Patients with rheumatoid arthritis
  • Patients with a history of traumatic injury to the hand
  • Cognitive or behavioral problems which would preclude
  • Unable to speak and understand English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Experimental Group with Cortisone Injection of affected digit(s) and nighttime orthosis

    The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.

    Device: Oval-8 ® Orthosis

  • Active comparator
    Control Group-No Orthosis

    The control group will be identical to the experimental group except without the use of a nighttime orthosis. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.

    Other: Cortisone injection only

Interventions

  • DeviceOval-8 ® Orthosis

    The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.

    Also known as: Cortisone Injection

  • OtherCortisone injection only

    The control group will receive a cortisone injection and be instructed to move their fingers normally

06

What researchers measure

Primary outcomes

  1. Resolution of Trigger Finger Symptoms

    Questionnaire used to determine resolution of Trigger Finger Symptoms

    Time frame: 6 Weeks

  2. Resolution of Trigger Finger Symptoms

    Questionnaire used to determine resolution of Trigger Finger Symptoms

    Time frame: 12 Weeks

Secondary outcomes

  1. Change in Pain

    Visual Analogue Scale for Pain (0 pain free to 10 severe pain)

    Time frame: 6 weeks

  2. Change in Pain

    Visual Analogue Scale for Pain (0 pain free to 10 severe pain)

    Time frame: 12 weeks

  3. Change in Perception of Function

    QuickDash scores (0% no functional limitations to 100% disabled)

    Time frame: 12 weeks

07

Study locations

1 of 2 sites recruiting
  • Cedars-Sinai Medical Center Outpatient Rehabilitation Hand Clinic
    Los Angeles, California 90048, United States
    Completed

    Not enrolling at this site.

  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be available for sharing.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05837286
Responsible party
Meghan McCullough, MD (Physician, Cedars-Sinai Medical Center) — Principal investigator
First posted
May 1, 2023
Start date
Aug 1, 2023
Primary completion
May 31, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Theodore Brown, BS
Contact
Theodore.Brown@cshs.org
800-700-6424
Meghan McCullough, MD
Contact
Meghan.McCullough@cshs.org
Meghan McCullough, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion